WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406322
Description: PIK-124 is a potent PI3K inhibitor.
MedKoo Cat#: 406322
Chemical Formula: C19H12ClFN2O3S2
Exact Mass: 433.99619
Molecular Weight: 434.89
Elemental Analysis: C, 52.47; H, 2.78; Cl, 8.15; F, 4.37; N, 6.44; O, 11.04; S, 14.75
Synonym: PIK124; PIK 124; PIK-124.
IUPAC/Chemical Name: (E)-4-(3-chloro-4-fluorobenzyl)-6-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
InChi Key: KWDKVVZOYYHCRG-FRKPEAEDSA-N
InChi Code: InChI=1S/C19H12ClFN2O3S2/c20-12-5-11(1-3-13(12)21)8-23-14-6-10(2-4-15(14)26-9-17(23)24)7-16-18(25)22-19(27)28-16/h1-7H,8-9H2,(H,22,25,27)/b16-7+
SMILES Code: O=C1N(CC2=CC=C(F)C(Cl)=C2)C3=CC(/C=C(SC(N4)=S)\C4=O)=CC=C3OC1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs
Storage Condition: 0 – 4 oC for short term (weeks to 1 month) or -20 oC for long terms (months to years).
Solubility: Soluble in DMSO, not soluble in water.
Shelf Life: >2 years if stored properly.
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 434.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. Torbett, Neil E.; Luna-moran, Antonio; Knight, Zachary A.; Houk, Andrew; Moasser, Mark; Weiss, William; Shokat, Kevan M.; Stokoe, David. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochemical Journal (2008), 415(1), 97-110
2. Kim, Tae-Wan; Dipaolo, Gilbert; Kang, Min Suk; Berman, Diego; McIntire, Laura Beth Johnson. Phosphoinositide modulation for the treatment of neurodegenerative diseases. PCT Int. Appl. (2008), WO 2008064244 A2 20080529
3. Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell (Cambridge, MA, United States) (2006), 125(4), 733-747.
4. Fan, Qi-Wen; Knight, Zachary A.; Goldenberg, David D.; Yu, Wei; Mostov, Keith E.; Stokoe, David; Shokat, Kevan M.; Weiss, William A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006), 9(5), 341-349.
5. Barvian, Nicole Chantel; Kolz, Christine Nylund; Para, Kimberly Suzanne; Patt, William Chester; Visnick, Melean. Preparation of benzoxazin-3-ones and derivatives as inhibitors of PI3K kinase for treating inflammations, cardiovascular diseases and cancers. PCT Int. Appl. (2004), WO 2004052373 A1 20040624.